Withdraw. Investigation into the impact of statin lipid-lowering medications in conjunction with triple enteric-coated bifidobacterium capsules to enhance the efficacy of lipoprotein(a) reduction

Investigation into the impact of statin lipid-lowering medications in conjunction with triple enteric-coated bifidobacterium capsules to enhance the efficacy of lipoprotein(a) reduction

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300075769

Enrollment

Unknown

Registered

2023-09-14

Start date

2023-04-01

Completion date

Unknown

Last updated

2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Interventions

Control group:Either atorvastatin 20mg Qn or rosuvastatin 10mg Qn

Experimental group:Administered two capsules of Bifidobacterium triple enteric-coated capsule twice a day, in addition to atorvastatin 20mg Qn or rosuvastatin 10mg Qn

Eligibility

Sex/Gender

All

Age

55 Years to 91 Years

Inclusion criteria

Inclusion criteria: (1) Adults meet the requirement of being prescribed statin lipid-lowering medications,including coronary artery disease, peripheral atherosclerosis, valvular heart disease, and hyperlipidemia who needed to regularly take statin lipid-lowering medications. (2) Be highly compliant.(3) Participants agreed to follow-up.

Exclusion criteria

Exclusion criteria: (1) Severe lung, liver, kidney dysfunction.(2)Severe arrhythmias, acute coronary syndrome and acute heart failure.(3) Mental illness, hemopathy or tumor ,inability to cooperate with. (4) Participants did not agree to follow-up.

Design outcomes

Primary

Measure	Time frame
Lp(a) (mg/l);	—

Countries

China

Contacts

Public ContactSong Yanxu

Affiliated Hospital of Qingdao University

prcsyx@163.com+86 188 6366 9510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026